Please ensure Javascript is enabled for purposes of website accessibility

The Benefits of Medical Marijuana, for Patients and Your Portfolio

By Olivia Zitkus - Apr 5, 2021 at 6:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cannabinoid-based medicines have made major advancements in research and uptake over the past few years.

Cannabis research -- even for medical purposes -- is highly restricted in the United States. But we have seen plenty of glimmers of hope about its benefits, and signals that cannabis can treat severe disease. Take, for instance, Jazz Pharmaceuticals' (JAZZ 1.36%) recent announcement of its acquisition of GW Phamaceuticals (GWPH). Through the deal, Jazz will bring cannabidiol-based Epidiolex, a treatment for certain types of seizures, into its portfolio.

Dr. Chanda Macias is a medical cannabis advocate, researcher, and dispensary owner. She joined Olivia Zitkus and Corinne Cardina of the Healthcare and Cannabis Bureau on a March 19 episode of Fool Live to talk about the medical benefits of marijuana, and why they're worth more investor attention.

Olivia Zitkus: Thank you. Hi, Dr. Chanda. I'm happy to be with you.

Dr. Chanda Macias: Hi. Thank you for having me.

Zitkus: Of course. I'm going to take it to the benefits of medical marijuana, you led in with the perfect little segue there, and talk about why cannabis is still classed by the way that it is in our legal system. My first question is, when you're telling people about the medical benefits of cannabis, what evidence do you site?

Macias: What's so interesting, Olivia, as a lot of people may or may not know, is that it's very restrictive to do research with cannabis in the United States. So most places that are conducting this research are outside of the U.S. like Israel, for example. I've been working with different companies. One is Ilera Therapeutics that has been operating in Pennsylvania, as well in Australia, they exchange on Australian exchange to have these clinical trials conducted. These are medicines that help people and patients for autism pain relief. When you think about why is that significant, well, GW Pharmaceuticals just had a M&A with Jazz Pharmaceuticals for over a billion dollars. Again, I'm triggering the audience out here. This is a real industry with real impact. When you think about cannabinoid medicine and how it's advanced over the last three to five years, what everyone will know is that its trajectory is going to be unbelievable. So for our scientists out there, our business investors that are considering to really look into cannabis, I think this is the time to take action and take it fast.

Zitkus: Awesome. Given all those things that you said about the medical benefits, do you have any big ideas or big picture reasons why you think marijuana is still labeled a Schedule 1 drug in the United States, given evidence of its ability to treat severe disease?

Macias: I do. Olivia, when I say that there is anecdotal research, just focusing and being in the industry for the last 10 years and working with thousands of patients, I've seen how it works within them. I can't claim it as research as you know, we discussed previously. But also what's important here is that the patients are directing that narrative, that they want to see this happen. So why isn't it happening as fast? Because it's very complicated. It's complicated because there is not only social justice reform, social equity issues involved, but also this is what prohibition looks like. This has happened with the alcohol industries, many other industries where we have to now piecemeal legalization so that it can open it up. So we have to remain patient, continue to educate our legislators on the benefits, not only health-wise, but economically, that's happening. When I say economically, Olivia, what I mean is that a lot of programs are expanding their medical and adult used programs to help with deficits in their budget today, especially by the results of COVID-19.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
Jazz Pharmaceuticals plc Stock Quote
Jazz Pharmaceuticals plc
$149.53 (1.36%) $2.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.